GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (XTAE:ORMP) » Definitions » E10

Oramed Pharmaceuticals (XTAE:ORMP) E10 : ₪-3.03 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Oramed Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Oramed Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was ₪0.146. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₪-3.03 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was -6.40% per year. During the past 5 years, the average E10 Growth Rate was -5.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Oramed Pharmaceuticals was -0.50% per year. The lowest was -8.30% per year. And the median was -3.95% per year.

As of today (2024-05-26), Oramed Pharmaceuticals's current stock price is ₪8.552. Oramed Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was ₪-3.03. Oramed Pharmaceuticals's Shiller PE Ratio of today is .


Oramed Pharmaceuticals E10 Historical Data

The historical data trend for Oramed Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals E10 Chart

Oramed Pharmaceuticals Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.46 -2.26 -2.48 -2.87 -2.95

Oramed Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.20 -3.34 -3.31 -2.95 -3.03

Competitive Comparison of Oramed Pharmaceuticals's E10

For the Biotechnology subindustry, Oramed Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oramed Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's Shiller PE Ratio falls into.



Oramed Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oramed Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.146/131.7762*131.7762
=0.146

Current CPI (Mar. 2024) = 131.7762.

Oramed Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201405 -0.659 100.373 -0.865
201408 -0.622 100.352 -0.817
201411 -0.695 99.635 -0.919
201502 -0.549 99.032 -0.731
201505 -0.549 100.333 -0.721
201508 -0.695 100.548 -0.911
201511 -0.768 100.135 -1.011
201602 -0.512 100.040 -0.674
201605 -0.549 101.355 -0.714
201608 -1.354 101.617 -1.756
201611 -0.732 101.829 -0.947
201702 -0.878 102.779 -1.126
201705 -0.549 103.256 -0.701
201708 -0.732 103.587 -0.931
201711 -0.659 104.072 -0.834
201802 -0.732 105.052 -0.918
201805 -1.098 106.148 -1.363
201808 -0.659 106.383 -0.816
201811 -0.915 106.338 -1.134
201902 -0.768 106.649 -0.949
201905 -0.841 108.048 -1.026
201908 -0.476 108.245 -0.579
201911 -0.549 108.519 -0.667
202002 -0.768 109.139 -0.927
202005 -0.366 108.175 -0.446
202008 -0.439 109.662 -0.528
202011 -0.841 109.793 -1.009
202102 -0.622 110.968 -0.739
202105 -0.622 113.576 -0.722
202108 -0.768 115.421 -0.877
202111 -0.805 117.269 -0.905
202203 -0.988 121.301 -1.073
202206 -0.988 125.017 -1.041
202209 -0.659 125.227 -0.693
202212 -0.805 125.222 -0.847
202303 -0.293 127.348 -0.303
202306 -0.110 128.729 -0.113
202309 -0.293 129.860 -0.297
202312 1.207 129.419 1.229
202403 0.146 131.776 0.146

Add all the adjusted EPS together and divide 10 will get our e10.


Oramed Pharmaceuticals  (XTAE:ORMP) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Oramed Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Oramed Pharmaceuticals (XTAE:ORMP) Business Description

Comparable Companies
Traded in Other Exchanges
Address
1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.